NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report

• <1% of cervical cancers are sarcomas. • Data on neurofibrosarcoma management is scarce. • Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance. • Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.

Detalles Bibliográficos
Autores principales: Wells, A.E., Mallen, A.M., Bui, M.M., Reed, D.R., Apte, S.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506462/
https://www.ncbi.nlm.nih.gov/pubmed/31080864
http://dx.doi.org/10.1016/j.gore.2019.04.006
_version_ 1783416855941087232
author Wells, A.E.
Mallen, A.M.
Bui, M.M.
Reed, D.R.
Apte, S.M.
author_facet Wells, A.E.
Mallen, A.M.
Bui, M.M.
Reed, D.R.
Apte, S.M.
author_sort Wells, A.E.
collection PubMed
description • <1% of cervical cancers are sarcomas. • Data on neurofibrosarcoma management is scarce. • Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance. • Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma.
format Online
Article
Text
id pubmed-6506462
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-65064622019-05-10 NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report Wells, A.E. Mallen, A.M. Bui, M.M. Reed, D.R. Apte, S.M. Gynecol Oncol Rep Case Report • <1% of cervical cancers are sarcomas. • Data on neurofibrosarcoma management is scarce. • Larotrectinib is approved for NTRK1 gene fusion tumors without acquired resistance. • Targeted therapy of tumor genes may expand treatment for a rare cervical sarcoma. Elsevier 2019-04-23 /pmc/articles/PMC6506462/ /pubmed/31080864 http://dx.doi.org/10.1016/j.gore.2019.04.006 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Wells, A.E.
Mallen, A.M.
Bui, M.M.
Reed, D.R.
Apte, S.M.
NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
title NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
title_full NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
title_fullStr NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
title_full_unstemmed NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
title_short NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
title_sort ntrk-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506462/
https://www.ncbi.nlm.nih.gov/pubmed/31080864
http://dx.doi.org/10.1016/j.gore.2019.04.006
work_keys_str_mv AT wellsae ntrk1fusioninendocervicalfibroblasticmalignantperipheralnervesheathtumormarkingeligibilityforlarotrectinibtherapyacasereport
AT mallenam ntrk1fusioninendocervicalfibroblasticmalignantperipheralnervesheathtumormarkingeligibilityforlarotrectinibtherapyacasereport
AT buimm ntrk1fusioninendocervicalfibroblasticmalignantperipheralnervesheathtumormarkingeligibilityforlarotrectinibtherapyacasereport
AT reeddr ntrk1fusioninendocervicalfibroblasticmalignantperipheralnervesheathtumormarkingeligibilityforlarotrectinibtherapyacasereport
AT aptesm ntrk1fusioninendocervicalfibroblasticmalignantperipheralnervesheathtumormarkingeligibilityforlarotrectinibtherapyacasereport

Ejemplares similares